Health Canada authorized tenecteplase for acute ischemic stroke, marking the country’s first new stroke treatment in nearly 27 years. The approval follows pivotal findings from the Canadian-led AcT trial, which evaluated the thrombolytic agent as an alternative to standard alteplase treatment within a 4.5-hour window.
Canadian stroke care has reached a milestone following a regulatory decision that reshapes clinical options for patients experiencing acute ischemic stroke. Hoffmann-La Roche Limited announced that Health Canada granted market authorization for the clot-dissolving agent TNKase, known generically as tenecteplase, with the approval taking effect effective November 13, 2025. The decision represents the first new stroke treatment authorized in nearly 27 years.
Pivotal Trial Evidence Behind the Canadian Authorization
The regulatory authorization rests upon data generated by the AcT trial, formally titled Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke. Led through the University of Calgary with financial support from the Canadian Institutes of Health Research and the Hotchkiss Brain Institute, the multicenter, open-label, parallel-group, randomized controlled trial enrolled patients across 22 primary and comprehensive stroke centers in Canada. Investigators evaluated adults presenting within 4.5 hours of symptom onset who experienced disabling neurological deficits from ischemic stroke, assigning participants on a 1:1 basis to receive either intravenous tenecteplase or the standard-of-care agent alteplase.
“The approval of tenecteplase for acute ischemic stroke marks an important moment in Canadian stroke care and exemplifies how innovative, investigator-initiated research can directly improve patient outcomes.”
Dr. Bijoy Menon, Professor and Head of Neurology at the Department of Clinical Neurosciences at the Cumming School of Medicine, University of Calgary and Principal Investigator of the AcT Trial
Following those trial results, tenecteplase has been integrated into the Canadian Stroke Best Practices recommendations as an alternative option for intravenous thrombolysis in eligible patients. Roche Canada plans to introduce a new 25 mg vial configuration in the coming months to facilitate administration.
Administration Advantages and Clinical Scope
Clinical guidelines mandate that treatment must be initiated within 4.5 hours from the onset of acute ischemic stroke symptoms and strictly after the exclusion of intracranial hemorrhage.
Broader ASA Guidelines Expand Pediatric and Adult Criteria
The Canadian regulatory milestone arrives alongside updated international standards. The American Stroke Association, a division of the American Heart Association, published its 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke in the journal Stroke, replacing the previous 2018 edition and 2019 update. The new framework introduces first-time guidance dedicated to pediatric stroke, addressing infants, children, and teens.
“These recommendations represent a major step toward standardized, evidence-based care for children. They also highlight how much more we still need to learn about pediatric stroke.”
Shyam Prabhakaran, M.D., M.S., FAHA, chair of the writing group for the guideline and the James Nelson and Anna Louise Raymond Professor of Neurology and chair of the department of neurology at the University of Chicago Medicine
Systemic Challenges and Future Prevention Strategies
Stroke remains a major public health crisis. According to statistics highlighted by the American Heart Association, stroke stands as the fourth leading cause of death in the United States, affecting nearly 800,000 Americans annually. In Canada, approximately 109,000 strokes occur each year—equating to roughly one stroke every five minutes—leaving about one million individuals living with long-term disability.
Clinical management must also contend with complex post-stroke complications, particularly immune suppression. Research indicates that ischemic stroke triggers central nervous system injury that leads to sympathetic outflow, causing a loss of splenic marginal zone B cells and suppressed circulating immunoglobulin M. That physiological cascade heightens patient vulnerability to bacterial pneumonia during recovery, pointing researchers toward future immunomodulatory strategies that protect immune function without compromising host defense.
Related reading
